



JC02 Rec'd PCT/PTC 01 SEP 2005 PCT

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	22	Application Number	10/535,447
		Filing Date	May 19, 2005
		First Named Inventor	Tai
		Art Unit	
		Examiner Name	
		Attorney Docket Number	EX03-086C-US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Reference copies
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Return Receipt Postcard
	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	EXELIXIS, INC.		
Signature			
Printed Name	Laleh Shayesteh		
Date	August 30, 2005	Reg. No.	47,937

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Laleh Shayesteh	Date	August 30, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.Y./



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Tai *et al.*

Application No.: 10/535,447

Filed: May 19, 2005

For: CCT6S AS MODIFIERS OF THE RB
PATHWAY AND METHODS OF USE

Confirmation No.: 8814

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-086C-US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:

WO0055174, Human Genome Sciences, September 21, 2000
WO0246465, OXFORD BIOMEDICA (UK) LIMITED, June 13, 2002
WO9520654, THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER
HOSPITAL, August 3, 1995

The above-references have not been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: August 30, 2005



Laleh Shayesteh

Reg. No. 47,937

Tel: (650) 837-8223; Fax: (650) 837-8234



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Tai *et al.*

Application No.: 10/535,447

Filed: May 19, 2005

For: CCT6S AS MODIFIERS OF THE RB
PATHWAY AND METHODS OF USE

Confirmation No.: 8814

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-086C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 C.F.R §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.


In accordance with 37 C.F.R §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R §1.97 (h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any required fees, if necessary, to Deposit No. 50-1108.

Respectfully submitted,

Dated: August 30, 2005


Laleh Shayesteh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/535,447
Filing Date	May 19, 2005
First Named Inventor	Tai
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-086C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Hillier, L.W., et al. Homo sapiens chaperonin containing TCP1, subunit 6A (zeta 1) (CCT6A), mRNA. GI:22095341 22-NOV-2004	
	2	Lee, Y.-K. and Yoo, Y.-D. Homo sapiens heat shock protein mRNA, complete cds. GI:14348899 12-JUN-2001	
	3	Wang, H., et al. Homo sapiens MoDP-2, MoDP-3 mRNA for acute morphine dependence related protein 2, acute morphine dependence related peptide 3, complete cds. GI:14517631 09-AUG-2001	
	4	Kubota, H., et al. Homo sapiens chaperonin containing TCP1, subunit 6B (zeta 2) (CCT6B), mRNA. GI:5729760 03-SEP-2004	
	5	NCBI Annotation Project. Homo sapiens chaperonin containing TCP1, subunit 6B (zeta 2) (CCT6B), mRNA. GI:14771917 01-AUG-2002	
	6	Ozaki, K., et al. Homo sapiens mRNA for testis-specific TCP20, complete cds. GI:1655415 09-FEB-2005	
	7	Strausberg, R.L., et al. Homo sapiens chaperonin containing TCP1, subunit 6B (zeta 2), mRNA (cDNA clone MGC:34021 IMAGE:4822253), complete cds. GI:34783247 28-JUL-2005	
	8	Yokota, S., et al. chaperonin containing TCP1, subunit 6A isoform A [Homo sapiens]. GI:4502643 23-APR-2005	
	9	Kubota, H., et al. chaperonin containing TCP1, subunit 6B (zeta 2) [Homo sapiens]. GI:5729761 03-SEP-2004	

Examiner Signature	/Misook Yu/	Date Considered	04/19/2009
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.Y./